98%
921
2 minutes
20
To further enhance the detection sensitivity and increase resolving power of top-down intact protein bioanalysis, middle-down approach was explored. An monoclonal antibody (mAb) was used as a model protein to evaluate quantitative bioanalytical assay performance and a disulfide linked dimer protein was investigated for its pharmacokinetics properties and catabolism by middle-down approach. For quantitation of the mAb, different subunits generated by middle-down approach provided different level of signal improvement in biological samples with Lc and half Fc giving five-times better sensitivity than intact mAb. For the dimer protein, middle-down analysis by reduction enabled effective differentiation of the unchanged protein and its oxidized form, and clearly elucidated their respective proteolytic catabolites.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/bio-2020-0315 | DOI Listing |
Proteomics
August 2025
Advanced Research Support Center, Ehime University, Ehime, Japan.
Top-down proteomics (TDP) is a powerful analytical approach for the highly sensitive measurement of intact proteoforms by mass spectrometry. However, its application to high molecular weight proteoforms remains challenging. Middle-down proteomics (MDP) offers a practical solution but requires pre-fractionation of the complex peptide mixture generated by limited digestion to successfully achieve trace-level peptide detection.
View Article and Find Full Text PDFMAbs
December 2025
Analytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Co-formulated antibody cocktails are becoming an increasingly popular therapeutic class; however, they present analytical challenges over traditional single monoclonal antibody (mAb) formulations. One paramount concern is the formation of heteromeric species that have unknown impacts on safety and efficacy. Consequently, effective approaches for identifying and characterizing high-molecular weight (HMW) impurities are critical to the successful development of this therapeutic class.
View Article and Find Full Text PDFAnal Chem
July 2025
Pharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, University of Tübingen, Auf der Morgenstelle 8, Tübingen 72076, Germany.
Therapeutic peptides are a rapidly growing field in research and drug development. While the majority of natural and synthetic therapeutic peptides have l-amino acids as building blocks, d-amino acid-containing peptides are found frequently in nonribosomal peptides or can be formed during peptide synthesis by epimerization. Thus, analytical methods are needed for the quality control of stereointegrity and the determination of absolute configurations.
View Article and Find Full Text PDFMass Spectrom Rev
June 2025
Verna & Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas, USA.
Histone proteins and their posttranslational modifications are central to chromatin structure and function. These modifications often occur in combinations, generating a diverse array of histone proteoforms that contribute to the dynamic regulation of chromatin architecture. Advancements in mass spectrometry-based proteomics, particularly top-down and middle-down approaches, have significantly enhanced our ability to characterize these proteoforms and elucidate PTM crosstalk.
View Article and Find Full Text PDFMol Cell Proteomics
July 2025
Spectrotech SAS, Lyon, France; Spectroswiss Sarl, Lausanne, Switzerland. Electronic address:
Therapeutic antibodies, primarily immunoglobulin G-based monoclonal antibodies, are developed to treat cancer, autoimmune disorders, and infectious diseases. Their large size, structural complexity, and heterogeneity pose significant analytical challenges, requiring advanced characterization techniques. This review traces the 30-year evolution of top-down (TD) and middle-down (MD) mass spectrometry (MS) for antibody analysis, beginning with their initial applications and highlighting key advances and challenges throughout this period.
View Article and Find Full Text PDF